2013年9月-2017年7月 華中科技大學(xué)同濟醫(yī)學(xué)院藥學(xué)院 學(xué)士
2017年9月-2022年7月 中國科學(xué)院上海藥物研究所藥物設(shè)計學(xué)專業(yè) 博士
2022年8月-2025年8月 中山大學(xué)腫瘤防治中心 博士后
2025年9月-至今 中國科學(xué)院廣州生物醫(yī)藥與健康研究院，副研究員
1.小細(xì)胞肺癌精準(zhǔn)治療靶標(biāo)發(fā)現(xiàn)與確證
2. 惡性腫瘤譜系靶向治療策略開發(fā)
1. 國家自然科學(xué)基金委員會,青年科學(xué)基金項目（C類）[原青年科學(xué)基金項目]，82404017，核黃素代謝關(guān)鍵酶RFK及其產(chǎn)物FMN異常活化調(diào)控非小細(xì)胞肺癌對于KRAS G12C抑制劑先天耐藥的功能與機制研究，2025-01-01至2027-12-31，30萬元，在研，主持
2. 中國博士后科學(xué)基金第74批面上資助，2023M744025，甲羥戊酸通路代謝異常參與非小細(xì)胞肺癌對于KRAS G12C抑制劑先天耐藥的功能和機制研究，2024-01至2026-01，8萬元，在研，主持
3. 國家資助博士后研究人員計劃B檔，GZB20230904，18萬元，主持
2022年度中國科學(xué)院地奧獎學(xué)金一等獎
2020-2021年度中國科學(xué)院大學(xué)三好學(xué)生
2017年度華中科技大學(xué)優(yōu)秀畢業(yè)生
2017年華中科技大學(xué)與德國馬爾堡大學(xué)藥學(xué)學(xué)科優(yōu)秀本科生交流項目
2016年度國家獎學(xué)金
1. Guowei Yin#*;Jing Huang#;Johnny Petela#;Hongmei Jiang;Yuetong Zhang;Siqi Gong;Jiaxin Wu;Bei Liu;Jianyou Shi*;Yijun Gao*;Targeting small GTPases: emerging grasps on previously untamable targets,pioneered by KRAS,Signal Transduction and Targeted Therapy,2023,8(1):212
2. Xiaobo Wang#;Jing Huang#;Fenglin Liu#;Qian Yu;Ruina Wang;Jiaqi Wang;Zewen Zhu;Juan Yu;Jun Hou;Joong Sup Shim;Wei Jiang;Zengxia Li;Yuanyuan Zhang*;Yongjun Dang*;Aurora A kinase inhibition elevates PD-L1 expression and compromises its anti-tumor efficacy,Journal of Clinical Investigation,2023,9(133):e161929
3. Jing Huang#;Xiaobo Wang#;Bing Li#;Shiyu Shen;Ruina Wang;Hongru Tao;Junchi Hu;Jin Yu;Hualiang Jiang;Kaixian Chen;Cheng Luo*;Yongjun Dang*;Yuanyuan Zhang*;L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression,Journal for ImmunoTherapy of Cancer,2022,10(6):e003957-e003957
4. Jinjin Peng#;Jiacheng Li#; Jing Huang#;Pan Xu;Huang Heming Huang;Yanjun Liu;Liang Yu;Yaxi Yang;Bing Zhou;Hualiang Jiang;Kaixian Chen;Yongjun Dang;Yuanyuan Zhang*;Cheng Luo*;Guangming Li*;p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization,Theranostics,2019,9(26):8344-8361
5. Fei Ye#;Jing Huang#;Hongbo Wang;Cheng Luo*;Kehao Zhao*;Targeting epigenetic machinery:Emerging novel allosteric inhibitors,Pharmacology & Therapeutics,2019,204: 107406
6. Liping Liao#,Wenzhen Dang#,Tingting Lin#,Jinghua Yu,Tonghai Liu,Wen Li,Senhao Xiao,Lei Feng,Jing Huang,Rong Fu,Jiacheng Li,Liping Liu,Mingchen Wang,Hongru Tao,Hualiang Jiang,Kaixian Chen,Xingxing Diao,Bing Zhou,Xiaoyan Shen*,Cheng Luo*. A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6. Acta Pharm Sin B. 2022,12(11):4180-4192.
7. Jianfeng Wang#,Chen Wan#,Pan Xu#,Xiao Li,Yongning Lu,Jin Di,Xiaomao Yin,Hao Jiang,Jing Huang,Huan Xiong,Fei Ye,Jia Jin,Yu Chen,Yiqian Xie,Zhifeng Chen,Hong Ding,Hao Zhang,Rongfeng Liu,Hao Jiang,Kaixian Chen,Zhiyi Yao,Cheng Luo*,Yiran Huang*,Yuanyuan Zhang*,Jin Zhang*. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics. 2021,11(11):5387-5403.
8. Zhongya Sun#,Hao Zhang#,Yuanyuan Zhang#,? Liping Liao#,Wen Zhou#,Fengcai Zhang,Fulin Lian, Jing Huang,Pan Xu,Rukang Zhang,Wenchao Lu,Mingrui Zhu,Hongru Tao,Feng Yang,Hong Ding,Shijie Chen,Liyan Yue,Bing Zhou,Naixia Zhang,Minjia Tan,Hao Jiang,Kaixian Chen,Bo Liu,Chuanpeng Liu*,Yongjun Dang*,Cheng Luo*. Covalent inhibitors allosterically block the activation of Rho family proteins and suppress cancer cell invasion. Adv Sci (Weinh). 2020,7(14):2000098.
9. Olga Pelikh#,Pascal-L Stahr#, Jing Huang,Martin Gerst,Patrik Scholz,Henriette Dietrich,Natalie Geisel,Cornelia M Keck*. Nanocrystals for improved dermal drug delivery. Eur J Pharm Biopharm. 2018,128:170-178.
